Compare KVHI & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KVHI | INDP |
|---|---|---|
| Founded | 1978 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 136.4M | 125.2M |
| IPO Year | 1996 | 2021 |
| Metric | KVHI | INDP |
|---|---|---|
| Price | $7.59 | $1.13 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 162.1K | ★ 833.7K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.33 | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $9,622,000.00 | N/A |
| Revenue This Year | $28.90 | N/A |
| Revenue Next Year | $31.85 | N/A |
| P/E Ratio | $188.00 | ★ N/A |
| Revenue Growth | ★ 3.82 | N/A |
| 52 Week Low | $5.09 | $0.92 |
| 52 Week High | $13.00 | $8.57 |
| Indicator | KVHI | INDP |
|---|---|---|
| Relative Strength Index (RSI) | 39.40 | 39.08 |
| Support Level | $7.32 | $0.92 |
| Resistance Level | $7.67 | $1.58 |
| Average True Range (ATR) | 0.32 | 0.18 |
| MACD | -0.00 | 0.06 |
| Stochastic Oscillator | 35.68 | 32.58 |
KVH Industries Inc provides integrated, end-to-end services, software, and hardware that support its customers' need for access to the Internet, VoIP, operations content, and entertainment services. It offers high-speed Internet and Voice over Internet Protocol (VoIP) services via satellite and integrated 5G/LTE cellular communications to mobile users at sea and on land. The company also provides commercially licensed entertainment, including news, sports, music, and movies, to commercial and leisure customers in the maritime, hotel, and retail markets. It operates in several geographic areas, including internationally. Revenues are generated from international locations, mainly consisting of Singapore, Canada, South America, European Union and other European countries, and other regions.
Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.